Methods and compositions for dengue virus vaccines

Patent metadata

Field	Value
Publication number	US-10053493-B2
Application number	US-201414392127-A
Country	US
Kind code	B2
Filing date	Jun 26, 2014
Priority date	Jun 26, 2013
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

First claim

What is claimed is:

1. A chimeric dengue virus E glycoprotein, comprising the amino acid sequence:

(SEQ ID NO: 3)

MRCVGIGNRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEA

TQLATLRKLCIEAKISNTTTDSRCPTQGEATLVEEQDTNFVCRRTFVDRG

WGNGCGLFGKGSLITCAKFKCVTK I EGK V VQYENLKYSVIVTVHTGDQHQ

VGNETTEHGT I ATITPQAPTSEIQLTDYGALTLDCSPRTGLDFNEM I LLT

M KN K A W M VHRQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEV

VVLGSQEGAMHTALTGATEIQ N SG G T S IFAGHLKCRLKMKLTLKGMSYVM

CTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIPFSSQDEKGVTQNGRL

ITANPIVTDKEKPVNIEAEPPFGESYIVVGAGEKALKLSWFKKG.

2. A chimeric dengue virus E glycoprotein, comprising the amino acid sequence:

(SEQ ID NO: 4)

MRCVGIGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIEL F KTE V

T NP AVLRKLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRG

WGNGCGLFGKGSLVTCAKFQCLEPIEGKVVQYENLKY S VI V TVHTGDQHQ

VGNET TEH G TI A T ITPQA P TSE IQ LT D YG A LGLECSPRTGLDFNEMILLT

MKNKAWMVHRQWFFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEV

VVLGSQEGAMHTALTGATEIQ T SG T T T IFAGHLKCRLKMDKLELKGMSYA

MCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNGR

LITANPVVTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKG.

3. A flavivirus particle or virus like particle (VLP) comprising the E glycoprotein of claim 1 .

4. A composition comprising the E glycoprotein of claim 1 in a pharmaceutically acceptable carrier.

5. A method of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of the E glycoprotein of claim 1 .

6. A flavivirus particle or virus like particle (VLP) comprising the E glycoprotein of claim 2 .

7. A composition comprising the E glycoprotein of claim 2 in a pharmaceutically acceptable carrier.

8. A method of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of the E glycoprotein of claim 2 .

Assignees

• Univ North Carolina Chapel Hill

Inventors

• Messer William
• Baric Ralph
• De Silva Aravinda
• Yount Boyd

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K16/116

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title